T. Rowe Price Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

T. Rowe Price Associates’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,616	Closed	-$15K	–	3058
2025 Q1	$15K	Hold	13,616	–	–	﹤0.01%	3016
2024 Q4	$24K	Sell	13,616 -836,003	-98%	-$2.01M	﹤0.01%	2985
2024 Q3	$2.11M	Sell	849,619 -196,745	-19%	-$534K	﹤0.01%	1611
2024 Q2	$2.53M	Sell	1,046,364 -51,912	-5%	-$165K	﹤0.01%	1453
2024 Q1	$4.45M	Buy	+1,098,276	New	+$4.14M	﹤0.01%	1249

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

T. Rowe Price Associates's ABOS Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 13,616 shares — an estimated $15K sold.

T. Rowe Price Associates first reported a position in ABOS in Q1 2024 and held it in 5 quarters. The position peaked at $4.45M in Q1 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

T. Rowe Price Associates reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 13,616 Acumen Pharmaceuticals shares in Q2 2025, an estimated $15K.
T. Rowe Price Associates first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 5 quarters.
T. Rowe Price Associates's Acumen Pharmaceuticals position peaked at $4.45M in Q1 2024.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.